skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: assunto: Aged remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel
A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel
Material Type:
Artigo 		Adicionar ao Meu Espaço

A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel

Flaherty, Keith T ; Schiller, Joan ; Schuchter, Lynn M ; Liu, Glenn ; Tuveson, David A ; Redlinger, Maryann ; Lathia, Chetan ; Xia, Chenghua ; Petrenciuc, Oana ; Hingorani, Sunil R ; Jacobetz, Michael A ; Van Belle, Patricia A ; Elder, David ; Brose, Marcia S ; Weber, Barbara L ; Albertini, Mark R ; O'Dwyer, Peter J

Clinical cancer research, 2008-08, Vol.14 (15), p.4836-4842 [Periódico revisado por pares]

Philadelphia, PA: American Association for Cancer Research

Texto completo disponível

Citações Citado por
2
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
Material Type:
Artigo 		Adicionar ao Meu Espaço

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

Tarhini, Ahmad A ; Kang, Ni ; Lee, Sandra J ; Hodi, F Stephen ; Cohen, Gary I ; Hamid, Omid ; Hutchins, Laura F ; Sosman, Jeffrey A ; Kluger, Harriet M ; Eroglu, Zeynep ; Koon, Henry B ; Lawrence, Donald P ; Kendra, Kari L ; Minor, David R ; Lee, Carrie B ; Albertini, Mark R ; Flaherty, Lawrence E ; Petrella, Teresa M ; Streicher, Howard ; Sondak, Vernon K ; Kirkwood, John M

Journal for immunotherapy of cancer, 2021-05, Vol.9 (5), p.e002535 [Periódico revisado por pares]

England: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
3
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609

Tarhini, Ahmad A ; Lee, Sandra J ; Hodi, F Stephen ; Rao, Uma N M ; Cohen, Gary I ; Hamid, Omid ; Hutchins, Laura F ; Sosman, Jeffrey A ; Kluger, Harriett M ; Eroglu, Zeynep ; Koon, Henry B ; Lawrence, Donald P ; Kendra, Kari L ; Minor, David R ; Lee, Carrie B ; Albertini, Mark R ; Flaherty, Lawrence E ; Petrella, Teresa M ; Streicher, Howard ; Sondak, Vernon K ; Kirkwood, John M

Journal of clinical oncology, 2020-02, Vol.38 (6), p.567-575 [Periódico revisado por pares]

United States: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
4
Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma: A Randomized Clinical Trial
Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma: A Randomized Clinical Trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma: A Randomized Clinical Trial

Carvajal, Richard D ; Sosman, Jeffrey A ; Quevedo, Jorge Fernando ; Milhem, Mohammed M ; Joshua, Anthony M ; Kudchadkar, Ragini R ; Linette, Gerald P ; Gajewski, Thomas F ; Lutzky, Jose ; Lawson, David H ; Lao, Christopher D ; Flynn, Patrick J ; Albertini, Mark R ; Sato, Takami ; Lewis, Karl ; Doyle, Austin ; Ancell, Kristin ; Panageas, Katherine S ; Bluth, Mark ; Hedvat, Cyrus ; Erinjeri, Joseph ; Ambrosini, Grazia ; Marr, Brian ; Abramson, David H ; Dickson, Mark Andrew ; Wolchok, Jedd D ; Chapman, Paul B ; Schwartz, Gary K

JAMA : the journal of the American Medical Association, 2014-06, Vol.311 (23), p.2397-2405 [Periódico revisado por pares]

Chicago, IL: American Medical Association

Texto completo disponível

Citações Citado por
5
A Phase I Study of Immunization Using Particle-Mediated Epidermal Delivery of Genes for gp100 and GM-CSF into Uninvolved Skin of Melanoma Patients
A Phase I Study of Immunization Using Particle-Mediated Epidermal Delivery of Genes for gp100 and GM-CSF into Uninvolved Skin of Melanoma Patients
Material Type:
Artigo 		Adicionar ao Meu Espaço

A Phase I Study of Immunization Using Particle-Mediated Epidermal Delivery of Genes for gp100 and GM-CSF into Uninvolved Skin of Melanoma Patients

CASSADAY, Ryan D ; SONDEL, Paul M ; HANK, Jacquelyn A ; MAHVI, David M ; ALBERTINI, Mark R ; KING, David M ; MACKLIN, Michael D ; GAN, Jacek ; WARNER, Tom F ; ZULEGER, Cindy L ; BRIDGES, Alan J ; SCHALCH, Heidi G ; KYUNG MANN KIM

Clinical cancer research, 2007-01, Vol.13 (2), p.540-549 [Periódico revisado por pares]

Philadelphia, PA: American Association for Cancer Research

Texto completo disponível

Citações Citado por
6
Effectiveness of pharmacotherapy for body dysmorphic disorder : A chart-review study
Effectiveness of pharmacotherapy for body dysmorphic disorder : A chart-review study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Effectiveness of pharmacotherapy for body dysmorphic disorder : A chart-review study

PHILLIPS, Katharine A ; ALBERTINI, Ralph S ; SINISCALCHI, Jason M ; KHAN, Ajaz ; ROBINSON, Marshall

The journal of clinical psychiatry, 2001-09, Vol.62 (9), p.721-727 [Periódico revisado por pares]

Memphis, TN: Physicians Postgraduate Press

Texto completo disponível

Citações Citado por
7
Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697)
Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697)

Agarwala, Sanjiv S ; Lee, Sandra J ; Yip, Waiki ; Rao, Uma N ; Tarhini, Ahmad A ; Cohen, Gary I ; Reintgen, Douglas S ; Evans, Terry L ; Brell, Joanna M ; Albertini, Mark R ; Atkins, Michael B ; Dakhil, Shaker R ; Conry, Robert M ; Sosman, Jeffrey A ; Flaherty, Lawrence E ; Sondak, Vernon K ; Carson, William E ; Smylie, Michael G ; Pappo, Alberto S ; Kefford, Richard F ; Kirkwood, John M

Journal of clinical oncology, 2017-03, Vol.35 (8), p.885-892 [Periódico revisado por pares]

United States: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
8
Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma
Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma

Albertini, Mark R. ; Yang, Richard K. ; Ranheim, Erik A. ; Hank, Jacquelyn A. ; Zuleger, Cindy L. ; Weber, Sharon ; Neuman, Heather ; Hartig, Greg ; Weigel, Tracey ; Mahvi, David ; Henry, Mary Beth ; Quale, Renae ; McFarland, Thomas ; Gan, Jacek ; Carmichael, Lakeesha ; Kim, KyungMann ; Loibner, Hans ; Gillies, Stephen D. ; Sondel, Paul M.

Cancer Immunology, Immunotherapy, 2018-10, Vol.67 (10), p.1647-1658 [Periódico revisado por pares]

Berlin/Heidelberg: Springer Berlin Heidelberg

Texto completo disponível

Citações Citado por
9
Phase II trial of hu14.18-IL2 for patients with metastatic melanoma
Phase II trial of hu14.18-IL2 for patients with metastatic melanoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase II trial of hu14.18-IL2 for patients with metastatic melanoma

Albertini, Mark R. ; Hank, Jacquelyn A. ; Gadbaw, Brian ; Kostlevy, Jordan ; Haldeman, Jennifer ; Schalch, Heidi ; Gan, Jacek ; Kim, KyungMann ; Eickhoff, Jens ; Gillies, Stephen D. ; Sondel, Paul M.

Cancer Immunology, Immunotherapy, 2012-12, Vol.61 (12), p.2261-2271 [Periódico revisado por pares]

Berlin/Heidelberg: Springer-Verlag

Texto completo disponível

Citações Citado por
10
Enrichment of melanoma-associated T cells in 6-thioguanine-resistant T cells from metastatic melanoma patients
Enrichment of melanoma-associated T cells in 6-thioguanine-resistant T cells from metastatic melanoma patients
Material Type:
Artigo 		Adicionar ao Meu Espaço

Enrichment of melanoma-associated T cells in 6-thioguanine-resistant T cells from metastatic melanoma patients

Zuleger, Cindy L ; Newton, Michael A ; Ma, Xiuyu ; Ong, Irene M ; Pei, Qinglin ; Albertini, Mark R

Melanoma research, 2020-02, Vol.30 (1), p.52-61 [Periódico revisado por pares]

England

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (80)

Data de Publicação 

De até
Refinar
  1. Antes de1992  (13)
  2. 1992Até1999  (16)
  3. 2000Até2006  (20)
  4. 2007Até2014  (16)
  5. Após 2014  (21)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (82)
  2. Japonês  (5)
  3. Espanhol  (2)
  4. Italiano  (1)
  5. Mais opções open sub menu

Neste Assunto:

  1. Aged
  2. Humans
  3. Middle Aged
  4. Male
  5. Female

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.